HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

AbstractBACKGROUND:
The role of β-catenin in cancer has been most studied in tumors of epithelial cell origin. The functional status and biological significance of this protein in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is unknown.
DESIGN AND METHODS:
ALK-positive anaplastic large cell lymphoma cell lines and patients' tumor samples were examined for status of β-catenin expression and signaling. The subcellular localization of β-catenin was assessed using immunohistochemistry, sub-cellular fractionation and confocal microscopy, while its transcriptional activity was studied using the TOPFlash/FOPFlash luciferase reporter assay. To examine the biological significance of β-catenin, short interfering RNA was used to knock-down its expression; the resulting biological effects were studied using trypan-blue exclusion and MTS assay, and the impact on its various downstream targets was assessed using quantitative real-time polymerase chain reaction and western blots.
RESULTS:
β-catenin was transcriptionally active in three of three ALK-positive anaplastic large cell lymphoma cell lines, and this finding correlates with the nuclear localization of β-catenin in these cells and the neoplastic cells identified in most of the patients' tumor samples. β-catenin is biologically significant in ALK-positive anaplastic large cell lymphoma, since down-regulation of β-catenin resulted in a significant reduction in their cell growth. Down-regulation of β-catenin led to a marked reduction in both the total protein level and the activated/phosphorylated form of STAT3, another signaling protein previously shown to be important in the pathogenesis of ALK-positive anaplastic large cell lymphoma. In contrast to some of the oncogenic tyrosine kinases, modulation of nucleophosmin-anaplastic lymphoma kinase expression did not result in any detectable change in the protein level, nuclear localization or tyrosine phosphorylation of β-catenin; however, inhibition of nucleophosmin-anaplastic lymphoma kinase expression significantly down-regulated the transcriptional activity of β-catenin.
CONCLUSIONS:
β-catenin signaling is constitutively active in ALK-positive anaplastic large cell lymphoma and represents a previously unknown mechanism by which the high levels of STAT3 expression and activation in these tumors are sustained. Our results suggest that the interaction between oncogenic tyrosine kinases and various cell signaling proteins may be more complex than previously believed.
AuthorsMona Anand, Raymond Lai, Pascal Gelebart
JournalHaematologica (Haematologica) Vol. 96 Issue 2 Pg. 253-61 (Feb 2011) ISSN: 1592-8721 [Electronic] Italy
PMID20971814 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • NPM1 protein, human
  • Nuclear Proteins
  • RNA, Messenger
  • RNA, Small Interfering
  • STAT3 Transcription Factor
  • beta Catenin
  • Nucleophosmin
  • Luciferases
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases
Topics
  • Anaplastic Lymphoma Kinase
  • Apoptosis
  • Blotting, Western
  • Cell Line, Tumor
  • Cell Proliferation
  • Enzyme-Linked Immunosorbent Assay
  • Fluorescent Antibody Technique
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunoenzyme Techniques
  • Immunoprecipitation
  • Luciferases (metabolism)
  • Lymphoma, Large-Cell, Anaplastic (genetics, metabolism, pathology)
  • Nuclear Proteins (metabolism)
  • Nucleophosmin
  • Phosphorylation
  • Prognosis
  • RNA, Messenger (genetics)
  • RNA, Small Interfering (genetics)
  • Receptor Protein-Tyrosine Kinases (metabolism)
  • Reverse Transcriptase Polymerase Chain Reaction
  • STAT3 Transcription Factor (metabolism)
  • Signal Transduction
  • Transcription, Genetic
  • beta Catenin (antagonists & inhibitors, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: